Maternal and Pediatric Precision Therapeutics Center at Vanderbilt (VICE-MPRINT)
Official title: Vanderbilt Integrated Center of Excellence in Maternal and Pediatric Precision Therapeutics (VICE-MPRINT)
Funded at Vanderbilt University Medical Center · NIH-11536362 · Data updated 2026-11-12
A Vanderbilt-led center aims to improve personalized medicines for pregnant people and children by using health data and new tools to study how genes affect drug responses and neonatal opioid withdrawal.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,237,710 |
| NIH project number | 3P50HD106446-05S1 |
| Project ID | NIH-11536362 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant individuals and children up to age 11, especially those in the first or third trimester and those affected by or at risk for conditions requiring precise pharmacotherapy.
✕Less likely to help
Patients outside the maternal-pediatric window or those not involved in pharmacogenomics research may not directly benefit.
What this research studies
This center brings researchers together to use electronic health records and other big datasets to better understand how genetics influences treatment in mothers and their babies. It focuses on pharmacogenomics in pregnancy and pediatrics and on identifying and validating gene-drug relationships in these groups. The project will also create new data science methods and tools to support precision therapeutics for children and women around birth. Training and collaboration across institutions will help translate findings into real-world care.
Why it matters
Potential benefit: If successful, the work could lead to safer, more effective medications and dosing decisions for pregnant people and newborns.
How similar studies have gone: Prior work with EHR-based phenotyping and pharmacogenomics in pediatric or maternal populations has shown promise, but larger, integrated efforts are still emerging.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Kannankeril, Prince Joseph — Vanderbilt University Medical Center
- Study coordinator: Kannankeril, Prince Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.